Experienced in Congenital Hyperinsulinism

Dr. Carla J. Greenbaum

Endocrinology
University Of Washington Medical Ctr, 1959 Ne Pacific St, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Congenital Hyperinsulinism
University Of Washington Medical Ctr, 1959 Ne Pacific St, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Carla Greenbaum is an Endocrinologist in Seattle, Washington. Dr. Greenbaum is rated as an Experienced provider by MediFind in the treatment of Congenital Hyperinsulinism. Her top areas of expertise are Type 1 Diabetes (T1D), Diabetic Ketoacidosis, Type 2 Diabetes (T2D), Congenital Hyperinsulinism, and Islet Cell Transplantation. Dr. Greenbaum is currently accepting new patients.

Her clinical research consists of co-authoring 165 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Congenital Hyperinsulinism.

Specialties
Endocrinology
Licenses
Internal Medicine in WA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

PacificSource
  • PPO
Premera
  • EPO
  • PPO

Locations

University Of Washington Medical Ctr, 1959 Ne Pacific St, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Type 1 Diabetes Extension Study
Type 1 Diabetes Extension Study
Enrollment Status: Recruiting
Publish Date: April 10, 2025
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 Administered Subcutaneously to Patients With Type 1 Diabetes Mellitus
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 Administered Subcutaneously to Patients With Type 1 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 20, 2025
Intervention Type: Other, Drug
Study Drugs: Pre-Proinsulin, TGF-Beta1, IL-10, IL-2
Study Phase: Phase 1
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes
Enrollment Status: Completed
Publish Date: June 06, 2024
Intervention Type: Drug
Study Drug: CTLA4-Ig (Abatacept)
Study Phase: Phase 2
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)
Enrollment Status: Terminated
Publish Date: April 09, 2024
Intervention Type: Drug
Study Drug: Hydroxychloroquine
Study Phase: Phase 2
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
Enrollment Status: Completed
Publish Date: February 01, 2023
Intervention Type: Biological, Drug
Study Drugs: AG019 - Low Dose, Teplizumab, AG019 - High Dose, AG019 - Low or High Dose
Study Phase: Phase 1/Phase 2
Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI)
Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI)
Enrollment Status: Completed
Publish Date: September 08, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus
AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: August 05, 2020
Intervention Type: Drug
Study Phase: Phase 2
Exploring Immunologic Effects of Oral Insulin in Relatives at Risk for Type 1
Exploring Immunologic Effects of Oral Insulin in Relatives at Risk for Type 1
Enrollment Status: Completed
Publish Date: July 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

164 Total Publications

Prevalence and severity of chronic kidney disease in a population with type 1 diabetes from a United States health system: a real-world cohort study.
Prevalence and severity of chronic kidney disease in a population with type 1 diabetes from a United States health system: a real-world cohort study.
Journal: Lancet regional health. Americas
Published: February 27, 2025
Similar Doctors
Distinguished in Congenital Hyperinsulinism
Dr. Christian Roth
Endocrinology
Distinguished in Congenital Hyperinsulinism
Dr. Christian Roth
Endocrinology

The Association Of Chrmc And University Physicians

4800 Sand Point Way Ne, 
Seattle, WA 
 (1.5 miles away)
206-526-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christian Roth is an Endocrinologist in Seattle, Washington. Dr. Roth is rated as a Distinguished provider by MediFind in the treatment of Congenital Hyperinsulinism. His top areas of expertise are Obesity, Obesity in Children, Congenital Hyperinsulinism, and Vitamin D Deficiency.

Advanced in Congenital Hyperinsulinism
Dr. Joohee Kim
Endocrinology
Advanced in Congenital Hyperinsulinism
Dr. Joohee Kim
Endocrinology
1130 N 185th St, Suite 201, 
Shoreline, WA 
 (8.1 miles away)
206-542-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joohee Kim is an Endocrinologist in Shoreline, Washington. Dr. Kim is rated as an Advanced provider by MediFind in the treatment of Congenital Hyperinsulinism. Her top areas of expertise are Silent Thyroiditis, Type 2 Diabetes (T2D), Diabetic Nephropathy, and Congenital Hyperinsulinism.

Experienced in Congenital Hyperinsulinism
Dr. Kristina Utzschneider
Endocrinology
Experienced in Congenital Hyperinsulinism
Dr. Kristina Utzschneider
Endocrinology
1660 S Columbian Way # 151, Va Puget Sound Health Care System, 
Seattle, WA 
 (5.9 miles away)
206-277-3568
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kristina Utzschneider is an Endocrinologist in Seattle, Washington. Dr. Utzschneider is rated as an Advanced provider by MediFind in the treatment of Congenital Hyperinsulinism. Her top areas of expertise are Type 2 Diabetes (T2D), Obesity, Non-Alcoholic Fatty Liver Disease, and Congenital Hyperinsulinism.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Greenbaum's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile